Asked by: Josh MacAlister (Labour - Whitehaven and Workington)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what progress the NHS England and College of Operating Department Practitioners working group has made on prescribing rights.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
In late 2020, NHS England launched a series of public consultations seeking views on proposals to amend the responsibilities for the prescribing, supply, and administration of medicines for the following professionals:
This work was undertaken as part of the Chief Professions Officers’ Medicines Mechanisms (CPOMM) programme. The Department is working with NHS England to consider the CPOMM’s consultations and progress the extension of responsibilities to supply, administer, or prescribe medicines under the Human Medicines Regulations 2012 (HMRs 2012) to regulated healthcare professionals, where a clear need and benefits have been identified.
For example, the Department recently completed work to amend the HMRs 2012 to allow dental hygienists and dental therapists to supply and administer specified medicines via exemptions, and pharmacy technicians to use Patient Group Directions. This legislation came into force in late June 2024. The Department will review priorities for progressing work in the CPOMM programme.
Asked by: Josh MacAlister (Labour - Whitehaven and Workington)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure sufficient supply of (a) creon and (b) other ADHD medications.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department has been working with suppliers to address current supply issues with pancreatic enzyme replacement therapy (PERT) used by patients with conditions such as cystic fibrosis and certain cancers, including pancreatic cancer. The supply issues are impacting countries throughout Europe and have been caused by limited availability of raw ingredients and manufacturing capacity constraints to produce volumes needed to meet demand. The Department is continuing to work with all suppliers of PERT to help resolve the supply issues in the short and longer term. This includes asking that they expedite deliveries, source stock from other markets, and increase production.
We have issued comprehensive guidance to healthcare professionals about these supply issues, which provides advice on how to manage patients whilst there is disruption to supply. This guidance is being kept under review and updates will be made as necessary. Serious Shortage Protocols are in place for Creon 10,000 and 25,000 capsules to limit prescriptions to one months’ supply whilst stocks are limited.
The Department has also been working hard with industry to help resolve supply issues with some attention deficit hyperactivity disorder (ADHD) medicines, which are also impacting countries throughout Europe. As a result of intensive work, some issues have been resolved. All strengths of lisdexamfetamine, atomoxetine capsules, and guanfacine prolonged-release tablets are now available. We are working to resolve the remaining issues impacting some strengths of methylphenidate. This includes asking suppliers to secure additional stocks, expedite deliveries where possible, and review plans to further build capacity to support continued growth in demand for the short and long-term.
The Department has worked with specialist clinicians to develop management advice for clinicians which includes consideration to prescribe available alternative brands of methylphenidate prolonged release tablets. We have widely disseminated our communications and continually update a list of currently available and unavailable ADHD products on the Specialist Pharmacy Service website, helping to ensure that those involved in the prescribing and dispensing of ADHD medications can make informed decisions with patients.